Clinical Trial Detail

NCT ID NCT02657551
Title A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Dana-Farber Cancer Institute
Indications

thyroid medullary carcinoma

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.